Personalized RNA-based Immunotherapy Systems

The present inventive concept integrates non-viral RNA delivery platforms with AI, IoT, blockchain, and new materials to create personalized immunotherapy systems that trigger multiple immune pathways, enabling real-time monitoring and optimization of immune responses.

The original patent disclosed a non-viral RNA delivery system for immunization, but it lacked the ability to personalize treatment, monitor immune responses in real-time, and optimize RNA sequences for individual patients. The present inventive concept addresses these limitations by incorporating advanced technologies to create a more powerful and effective system.

The inventive concept comprises a non-viral RNA delivery platform, a blockchain-based decentralized data storage for storing patient-specific genetic information, and an AI-driven analytics module for predicting optimal RNA sequences for individual patients. The system can be further integrated with IoT sensors for real-time monitoring of immune responses, allowing for adjustments to the RNA composition in real-time. Additionally, the system can utilize new materials with enhanced immunogenic properties to further enhance the immune response.

The integration of AI, IoT, blockchain, and new materials with non-viral RNA delivery platforms to create personalized immunotherapy systems that trigger multiple immune pathways is novel and non-obvious compared to the original patent. The use of AI-driven analytics to predict optimal RNA sequences and the incorporation of IoT sensors for real-time monitoring of immune responses are particularly innovative.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT sensor configurations, or new materials with varying immunogenic properties. Variations could also include the integration of additional technologies, such as machine learning or natural language processing, to further enhance the system's capabilities.

The present inventive concept has significant commercial potential in the fields of personalized medicine, immunotherapy, and vaccine development. The system's ability to trigger multiple immune pathways and provide real-time monitoring and optimization of immune responses could lead to improved treatment outcomes and reduced healthcare costs.